Skip to content
Subscriber Only

Fund That Surged on Rocket Looks to Next Rare Disease Windfall

  • Investor gains $500 million in a day on Rocket Pharmaceuticals
  • RTW Investments sees more opportunity in gene therapies

RTW Investments LP has cemented its place as one of the top performing health-care hedge funds after an almost $500 million gain from its largest investment, Rocket Pharmaceuticals Inc.

Rocket -- which develops treatments for rare diseases in children -- surged 83% in a single day last week on positive results from an experimental gene therapy for a heart muscle disorder.